Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid CarcinomaJennifer Wang, Maria E. Cabanillas, Mark Zafereo et al.|Thyroid|2019Cited by 229
Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and AnalysesJack Phan, Steven J. Frank, Terence T. Sio et al.|International Journal of Radiation Oncology*Biology*Physics|2016Cited by 149
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatmentDavid C. Shonka, Gregory W. Randolph, Ashish V. Chintakuntlawar et al.|Head & Neck|2022Cited by 110
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid CarcinomaSarah Hamidi, Maria E. Cabanillas, Priyanka Iyer et al.|Thyroid|2024Cited by 72
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid CancerSarah Hamidi, Maria E. Cabanillas, Ramona Dadu et al.|JAMA Oncology|2024Cited by 35